Clinicodemographic characteristics by SVI score
| Characteristic . | N . | Total SVI score . | ||||
|---|---|---|---|---|---|---|
| 0.000-0.199, n = 5329 (0.7%) . | 0.200-0.399, n = 180 407 (23%) . | 0.400-0.599, n = 403 072 (51%) . | 0.600-0.799, n = 194 591 (24%) . | 0.800-0.999, n = 12 606 (1.6%) . | ||
| Age, y | 796 005 | |||||
| 20-44 | 636 (12%) | 22 878 (13%) | 53 319 (13%) | 26 033 (13%) | 1 425 (11%) | |
| 45-64 | 1851 (35%) | 55 575 (31%) | 125 616 (31%) | 61 535 (32%) | 4 021 (32%) | |
| 65-84 | 2394 (45%) | 85 236 (47%) | 188 030 (47%) | 90 022 (46%) | 6 100 (48%) | |
| 85+ | 448 (8.4%) | 16 718 (9.3%) | 36 107 (9.0%) | 17 001 (8.7%) | 1 060 (8.4%) | |
| Sex | 796 005 | |||||
| Male | 3045 (57%) | 99 472 (55%) | 223 161 (55%) | 107 960 (55%) | 6 975 (55%) | |
| Female | 2284 (43%) | 80 935 (45%) | 179 911 (45%) | 86 631 (45%) | 5 631 (45%) | |
| Race | 796 005 | |||||
| White | 4751 (89%) | 161 205 (89%) | 299 379 (74%) | 124 389 (64%) | 7 897 (63%) | |
| Hispanic | 359 (6.7%) | 5 828 (3.2%) | 29 407 (7.3%) | 35 535 (18%) | 2 726 (22%) | |
| Black | 88 (1.7%) | 8 071 (4.5%) | 42 631 (11%) | 21 344 (11%) | 1 379 (11%) | |
| Asian or Pacific Islander | 49 (0.9%) | 3 731 (2.1%) | 27 394 (6.8%) | 10 423 (5.4%) | 132 (1.0%) | |
| Unknown | 50 (0.9%) | 1 217 (0.7%) | 3 053 (0.8%) | 2 000 (1.0%) | 77 (0.6%) | |
| Native American | 32 (0.6%) | 355 (0.2%) | 1 208 (0.3%) | 900 (0.5%) | 395 (3.1%) | |
| Region | 796 005 | |||||
| Midwest | 790 (15%) | 46 185 (26%) | 72 582 (18%) | 3 014 (1.5%) | 0 (0%) | |
| Northeast | 2216 (42%) | 62 736 (35%) | 56 077 (14%) | 10 727 (5.5%) | 0 (0%) | |
| South | 1367 (26%) | 17 355 (9.6%) | 71 345 (18%) | 41 211 (21%) | 4 502 (36%) | |
| West | 956 (18%) | 54 131 (30%) | 203 068 (50%) | 139 639 (72%) | 8 104 (64%) | |
| Disease class | 796 005 | |||||
| ALL | 82 (1.5%) | 2 530 (1.4%) | 6 192 (1.5%) | 4 028 (2.1%) | 276 (2.2%) | |
| Acute myeloid leukemia | 478 (9.0%) | 16 666 (9.2%) | 38 657 (9.6%) | 19 191 (9.9%) | 1 226 (9.7%) | |
| Aleukemic, subleukemic, and NOS | 36 (0.7%) | 1 632 (0.9%) | 3 744 (0.9%) | 1 995 (1.0%) | 168 (1.3%) | |
| Chronic lymphocytic leukemia | 786 (15%) | 23 594 (13%) | 47 246 (12%) | 21 088 (11%) | 1 420 (11%) | |
| Chronic myeloid leukemia | 219 (4.1%) | 7 779 (4.3%) | 17 596 (4.4%) | 8 581 (4.4%) | 609 (4.8%) | |
| Hodgkin, extranodal | 8 (0.2%) | 288 (0.2%) | 616 (0.2%) | 272 (0.1%) | 18 (0.1%) | |
| Hodgkin, nodal | 347 (6.5%) | 11 785 (6.5%) | 25 132 (6.2%) | 11 416 (5.9%) | 686 (5.4%) | |
| Myeloma | 763 (14%) | 26 562 (15%) | 63 002 (16%) | 31 103 (16%) | 2 263 (18%) | |
| Non-Hodgkin, extranodal | 779 (15%) | 26 003 (14%) | 62 066 (15%) | 30 214 (16%) | 1 779 (14%) | |
| Non-Hodgkin, nodal | 1701 (32%) | 58 775 (33%) | 128 745 (32%) | 62 469 (32%) | 3 865 (31%) | |
| Other acute leukemia | 42 (0.8%) | 1 650 (0.9%) | 3 480 (0.9%) | 1 477 (0.8%) | 97 (0.8%) | |
| Other lymphocytic leukemia | 65 (1.2%) | 2 249 (1.2%) | 4 513 (1.1%) | 1 958 (1.0%) | 134 (1.1%) | |
| Other myeloid/monocytic leukemia | 23 (0.4%) | 894 (0.5%) | 2 083 (0.5%) | 799 (0.4%) | 65 (0.5%) | |
| Vital status on last follow-up | 796 005 | |||||
| Alive | 2608 (49%) | 68 071 (38%) | 147 569 (37%) | 78 982 (41%) | 4 817 (38%) | |
| Dead | 2721 (51%) | 112 336 (62%) | 255 503 (63%) | 115 609 (59%) | 7 789 (62%) | |
| Characteristic . | N . | Total SVI score . | ||||
|---|---|---|---|---|---|---|
| 0.000-0.199, n = 5329 (0.7%) . | 0.200-0.399, n = 180 407 (23%) . | 0.400-0.599, n = 403 072 (51%) . | 0.600-0.799, n = 194 591 (24%) . | 0.800-0.999, n = 12 606 (1.6%) . | ||
| Age, y | 796 005 | |||||
| 20-44 | 636 (12%) | 22 878 (13%) | 53 319 (13%) | 26 033 (13%) | 1 425 (11%) | |
| 45-64 | 1851 (35%) | 55 575 (31%) | 125 616 (31%) | 61 535 (32%) | 4 021 (32%) | |
| 65-84 | 2394 (45%) | 85 236 (47%) | 188 030 (47%) | 90 022 (46%) | 6 100 (48%) | |
| 85+ | 448 (8.4%) | 16 718 (9.3%) | 36 107 (9.0%) | 17 001 (8.7%) | 1 060 (8.4%) | |
| Sex | 796 005 | |||||
| Male | 3045 (57%) | 99 472 (55%) | 223 161 (55%) | 107 960 (55%) | 6 975 (55%) | |
| Female | 2284 (43%) | 80 935 (45%) | 179 911 (45%) | 86 631 (45%) | 5 631 (45%) | |
| Race | 796 005 | |||||
| White | 4751 (89%) | 161 205 (89%) | 299 379 (74%) | 124 389 (64%) | 7 897 (63%) | |
| Hispanic | 359 (6.7%) | 5 828 (3.2%) | 29 407 (7.3%) | 35 535 (18%) | 2 726 (22%) | |
| Black | 88 (1.7%) | 8 071 (4.5%) | 42 631 (11%) | 21 344 (11%) | 1 379 (11%) | |
| Asian or Pacific Islander | 49 (0.9%) | 3 731 (2.1%) | 27 394 (6.8%) | 10 423 (5.4%) | 132 (1.0%) | |
| Unknown | 50 (0.9%) | 1 217 (0.7%) | 3 053 (0.8%) | 2 000 (1.0%) | 77 (0.6%) | |
| Native American | 32 (0.6%) | 355 (0.2%) | 1 208 (0.3%) | 900 (0.5%) | 395 (3.1%) | |
| Region | 796 005 | |||||
| Midwest | 790 (15%) | 46 185 (26%) | 72 582 (18%) | 3 014 (1.5%) | 0 (0%) | |
| Northeast | 2216 (42%) | 62 736 (35%) | 56 077 (14%) | 10 727 (5.5%) | 0 (0%) | |
| South | 1367 (26%) | 17 355 (9.6%) | 71 345 (18%) | 41 211 (21%) | 4 502 (36%) | |
| West | 956 (18%) | 54 131 (30%) | 203 068 (50%) | 139 639 (72%) | 8 104 (64%) | |
| Disease class | 796 005 | |||||
| ALL | 82 (1.5%) | 2 530 (1.4%) | 6 192 (1.5%) | 4 028 (2.1%) | 276 (2.2%) | |
| Acute myeloid leukemia | 478 (9.0%) | 16 666 (9.2%) | 38 657 (9.6%) | 19 191 (9.9%) | 1 226 (9.7%) | |
| Aleukemic, subleukemic, and NOS | 36 (0.7%) | 1 632 (0.9%) | 3 744 (0.9%) | 1 995 (1.0%) | 168 (1.3%) | |
| Chronic lymphocytic leukemia | 786 (15%) | 23 594 (13%) | 47 246 (12%) | 21 088 (11%) | 1 420 (11%) | |
| Chronic myeloid leukemia | 219 (4.1%) | 7 779 (4.3%) | 17 596 (4.4%) | 8 581 (4.4%) | 609 (4.8%) | |
| Hodgkin, extranodal | 8 (0.2%) | 288 (0.2%) | 616 (0.2%) | 272 (0.1%) | 18 (0.1%) | |
| Hodgkin, nodal | 347 (6.5%) | 11 785 (6.5%) | 25 132 (6.2%) | 11 416 (5.9%) | 686 (5.4%) | |
| Myeloma | 763 (14%) | 26 562 (15%) | 63 002 (16%) | 31 103 (16%) | 2 263 (18%) | |
| Non-Hodgkin, extranodal | 779 (15%) | 26 003 (14%) | 62 066 (15%) | 30 214 (16%) | 1 779 (14%) | |
| Non-Hodgkin, nodal | 1701 (32%) | 58 775 (33%) | 128 745 (32%) | 62 469 (32%) | 3 865 (31%) | |
| Other acute leukemia | 42 (0.8%) | 1 650 (0.9%) | 3 480 (0.9%) | 1 477 (0.8%) | 97 (0.8%) | |
| Other lymphocytic leukemia | 65 (1.2%) | 2 249 (1.2%) | 4 513 (1.1%) | 1 958 (1.0%) | 134 (1.1%) | |
| Other myeloid/monocytic leukemia | 23 (0.4%) | 894 (0.5%) | 2 083 (0.5%) | 799 (0.4%) | 65 (0.5%) | |
| Vital status on last follow-up | 796 005 | |||||
| Alive | 2608 (49%) | 68 071 (38%) | 147 569 (37%) | 78 982 (41%) | 4 817 (38%) | |
| Dead | 2721 (51%) | 112 336 (62%) | 255 503 (63%) | 115 609 (59%) | 7 789 (62%) | |
NOS, not otherwise specified.